TY - JOUR
T1 - Cutaneous manifestations of pediatric lupus
AU - Arkin, Lisa M.
AU - Nguyen, Cordellia
AU - Klein-Gitelman, Marisa
N1 - Funding Information:
L.A. has received grant funding from the Childhood Arthritis & Rheumatology Research Alliance (CARRA) and the Pediatric Dermatology Research Alliance (PeDRA) for work related to discoid lupus in children. No other authors report financial conflicts of interest.
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Purpose of review To review recent evidence on cutaneous manifestations of lupus, with a focus on evidence for pediatric patients. Recent findings Cutaneous manifestations of SLE are common and may precede signs or symptoms of systemic disease. Early recognition and initiation of therapy improves quality of life by reducing cutaneous disease activity. Antimalarials are first line for moderate-to-severe disease. Photo protection is a critical component of therapy and perhaps the only modifiable risk factor for SLE. Recognition of cutaneous vasculopathy may reduce mortality from vascular occlusion. Summary There is a critical need for better understanding of pathogenesis, risk factors and outcomes in cutaneous lupus to determine optimal treatment and surveillance strategies. Correlation of clinical phenotypes with biomarkers may help to stratify patients, optimize targeted interventions, and influence prognosis.
AB - Purpose of review To review recent evidence on cutaneous manifestations of lupus, with a focus on evidence for pediatric patients. Recent findings Cutaneous manifestations of SLE are common and may precede signs or symptoms of systemic disease. Early recognition and initiation of therapy improves quality of life by reducing cutaneous disease activity. Antimalarials are first line for moderate-to-severe disease. Photo protection is a critical component of therapy and perhaps the only modifiable risk factor for SLE. Recognition of cutaneous vasculopathy may reduce mortality from vascular occlusion. Summary There is a critical need for better understanding of pathogenesis, risk factors and outcomes in cutaneous lupus to determine optimal treatment and surveillance strategies. Correlation of clinical phenotypes with biomarkers may help to stratify patients, optimize targeted interventions, and influence prognosis.
KW - Cutaneous lupus erythematosus
KW - Cutaneous manifestations of systemic disease
KW - Pediatric
KW - Scarring
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85070790394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070790394&partnerID=8YFLogxK
U2 - 10.1097/BOR.0000000000000610
DO - 10.1097/BOR.0000000000000610
M3 - Review article
C2 - 31085940
AN - SCOPUS:85070790394
SN - 1040-8711
VL - 31
SP - 411
EP - 420
JO - Current opinion in rheumatology
JF - Current opinion in rheumatology
IS - 5
ER -